May 23rd 2024

Published in Viruses: CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses

Published in Viruses: CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses

The CARE member, Centre Hospitalier Universitaire Vaudois (CHUV), has published a paper on the differences observed between hospitalised and non-hospitalised patients following SARS-CoV-2 infection in terms of the levels of detectable anti-SARS-CoV-2 neutralising responses and antibodies titres, which were significantly lower in non-hospitalised donors.

The aim of this work was to identify early factors that could predict the severity of SARS-CoV-2 infection. To this end, plasma and peripheral blood mononuclear cells were collected at 6 months post-onset of symptoms from 72 patients with severe COVID-19 who required hospitalization (31 of whom were admitted to intensive care) and 23 individuals who did not require hospitalization.

Blood and serum samples collected at 6 months post-onset of symptoms were used to characterize the ex vivo cellular and serum immune signatures, using mass cytometry and multiplex bead assays, respectively. The overall results suggest that the balance between the cytokines CXCL12 and CXCL13 may be an early predictive marker associated with the magnitude and the quality of SARS-CoV-2 antibody and memory B cell responses.

This work may help to improve the care of infected patients through enabling a better understanding of the immunological markers associated with long-lasting immune responses to SARS-CoV-2.

To learn more, click here: CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses